RESUMO
Between August and November 2012 a severe outbreak of gastroenteritis occurred on Réunion Island, affecting more than 50,000 cases, particularly young children. Virological analyses showed that the virus responsible for this epidemic was rotavirus. Genotyping of stool samples indicated circulation of rotavirus type G3P[8] but also G12P[8], highlighting the risk of global emergence of this genotype in the coming years.
Assuntos
Surtos de Doenças , Gastroenterite/epidemiologia , Infecções por Rotavirus/epidemiologia , Rotavirus/isolamento & purificação , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Diarreia/epidemiologia , Diarreia/virologia , Serviço Hospitalar de Emergência/estatística & dados numéricos , Feminino , Clínicos Gerais/estatística & dados numéricos , Humanos , Masculino , Pessoa de Meia-Idade , Reunião/epidemiologia , Rotavirus/classificação , Rotavirus/genética , Infecções por Rotavirus/prevenção & controle , Infecções por Rotavirus/virologia , Vacinas contra Rotavirus/administração & dosagem , Estações do Ano , Adulto JovemRESUMO
In Reunion Island, the risk of emerging infectious diseases lies mainly in several viral zoonoses: West Nile fever, Sindbis virus, Nipah virus, Wesselsbron virus, Rift Valley fever and Japanese encephalitis. There morbidity and consequences are more or less important but they all have a non-negligible epidemic potential, so they have to be monitored. Indeed, the struggle against these emerging infectious diseases requires an early detection of the cases, thus a surveillance system capable of detecting them as early as possible, thanks to a real international network of information, warning and prevention.
Assuntos
Doenças Transmissíveis Emergentes/epidemiologia , Viroses/epidemiologia , Zoonoses/epidemiologia , Animais , Doenças Transmissíveis Emergentes/etiologia , Surtos de Doenças/prevenção & controle , Humanos , Reunião/epidemiologia , Risco , Zoonoses/etiologiaRESUMO
Since January 2012, 20 autochthonous cases of dengue virus (DENV) infection have been identified in Réunion. The first cases were detected on the western coast, but the two co-circulating viruses (DENV-1 and DENV-3) seemed to have spread later to different cities of the island. There is a non-negligible risk of increase in viral transmission over the following weeks, so health professionals and public health authorities in Réunion are preparing to face a potential epidemic.
Assuntos
Doenças Transmissíveis Emergentes/epidemiologia , Dengue/epidemiologia , Controle de Infecções/métodos , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Doenças Transmissíveis Emergentes/transmissão , Dengue/transmissão , Vírus da Dengue/imunologia , Surtos de Doenças , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reunião/epidemiologiaRESUMO
In March 2010, a new outbreak of chikungunya infection was detected in the west of Reunion Island. An investigation was launched to describe the incident cases occurrence and to raise hypotheses on factors that could explain the occurrence of this outbreak. All probable or confirmed cases detected by the surveillance system in the western area between March 1st and July 2nd, 2010 were included in the investigation. A standardized questionnaire was performed by phone, including sociodemographic, environmental and behaviour data. A total of 74 cases were described (i.e. response rate of 72%). They were mainly women (sex ratio M/F=0.7), all ages were represented. Most of them (76%) resided in a house; 31% had recently moved, including 22% from metropolitan France. They reported to have been more exposed to mosquitoes and to infected patients than during the major epidemic of 2005-2006. In addition, 41% reported to have reduced their protection against mosquitoes. The results suggest that several concomitant factors contributed to this outbreak: the reintroduction of the chikungunya virus in the island, the population characteristics and environmental factors.
Assuntos
Infecções por Alphavirus/epidemiologia , Infecções por Alphavirus/virologia , Vírus Chikungunya/isolamento & purificação , Doenças Transmissíveis Emergentes/epidemiologia , Doenças Transmissíveis Emergentes/virologia , Surtos de Doenças , Adulto , Aedes , Idoso , Animais , Febre de Chikungunya , Vírus Chikungunya/genética , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Vigilância da População/métodos , Reunião/epidemiologia , Fatores de Risco , Inquéritos e Questionários , Adulto JovemRESUMO
In the Southern hemisphere, Réunion Island acts as a sentinel for infections preferentially occurring during the austral winter that are likely to reach the Northern hemisphere a few months later. We relate the main features concerning patients that were admitted during years 2009 and 2010 in our intensive care unit with an A(H1N1)v2009 infection, mainly for acute respiratory distress. Demographic, clinical, and biological data as well as given medications and outcome were prospectively collected among all PCR-confirmed influenza-infected patients. In 2009 and 2010, 25 patients met the criteria. Patients' median age was 40.4 (±17.4) years. Most of them (22/25) had comorbidities such as: chronic diseases, overweight, obesity, pregnancy, and Down syndrome. Maximum bed-occupation rate was 10 days per million inhabitants. Main diagnosis for ICU admission was virus-related pneumonia. Twenty-two out of 25 patients needed mechanical ventilation, some required rescue therapies such as extracorporeal membranous oxygenation (ECMO) or hi-frequency oscillation ventilation (HFOV), both only available in few French hospitals. Within the study period, 12 patients died (48%) mainly of multi-organ failure. Through 2009 and 2010 autumn and winter periods, for several weeks, the A(H1N1)v2009 virus infection resulted in a significant increase of workload in Réunion Island ICUs. In 2010, the failure of the mass immunization campaign, particularly among the at-risk groups, led to severe cases of A(H1N1)v2009 infections, particularly among patients with comorbidities. Our data may contribute toward better management of influenza virus pandemics in the future.
Assuntos
Epidemias , Vírus da Influenza A Subtipo H1N1 , Influenza Humana/epidemiologia , Adolescente , Adulto , Idoso , Antivirais/uso terapêutico , Terapia Combinada , Comorbidade , Suscetibilidade a Doenças , Feminino , Humanos , Vírus da Influenza A Subtipo H1N1/genética , Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Influenza Humana/complicações , Influenza Humana/terapia , Influenza Humana/virologia , Unidades de Terapia Intensiva/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Insuficiência de Múltiplos Órgãos/etiologia , Insuficiência de Múltiplos Órgãos/mortalidade , Admissão do Paciente/estatística & dados numéricos , Reação em Cadeia da Polimerase , Gravidez , Complicações Infecciosas na Gravidez/epidemiologia , Complicações Infecciosas na Gravidez/virologia , Estudos Prospectivos , Respiração Artificial , Síndrome do Desconforto Respiratório/epidemiologia , Síndrome do Desconforto Respiratório/etiologia , Reunião/epidemiologia , Adulto JovemRESUMO
(R)-3-(1-[2-(4-benzoyl-2-(3,4-difluorophenyl)-morpholin-2-yl)- ethyl]-4-phenylpiperidin-4-yl)-1-dimethylurea (SR 144190) is a new non-peptide antagonist of tachykinin NK2 receptors. SR 144190 potently and selectively inhibited neurokinin A binding to NK2 receptors from various species, including humans. In in vitro functional assays, it was a potent, selective and competitive antagonist of NK2 receptors with apparent affinities (pA2 values) between 9.08 and 10.10. In vivo, SR 144190 blocked [Nle10]neurokinin A-(4-10)-induced bronchoconstriction in guinea pigs (ID50 = 21 micrograms kg-1 i.v. and 250 micrograms kg-1 i.d.) and [beta Ala8]neurokinin A-(4-10)-induced urinary bladder contraction in rats (ID50 = 11 micrograms kg-1 i.v. and 190 micrograms kg-1 i.d.). It prevented citric acid-induced cough and airway hyperresponsiveness to acetylcholine in guinea pigs (1 mg kg-1 i.p.) as well as castor oil-induced diarrhoea in rats (0.01-10 micrograms kg-1 s.c. or p.o). Finally, it blocked the turning behaviour induced by intrastriatal injections of [Nle10]neurokinin A-(4-10) in mice (ID50 = 3 micrograms kg-1 i.v. and 16 micrograms kg-1 p.o.).
Assuntos
Compostos de Metilureia/farmacologia , Morfolinas/farmacologia , Receptores da Neurocinina-2/antagonistas & inibidores , Animais , Ligação Competitiva , Disponibilidade Biológica , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/metabolismo , Cricetinae , Sistema Digestório/efeitos dos fármacos , Sistema Digestório/metabolismo , Feminino , Gerbillinae , Cobaias , Humanos , Técnicas In Vitro , Masculino , Compostos de Metilureia/química , Compostos de Metilureia/farmacocinética , Camundongos , Morfolinas/química , Morfolinas/farmacocinética , Ratos , Sistema Respiratório/efeitos dos fármacos , Sistema Respiratório/metabolismo , Sistema Urinário/efeitos dos fármacos , Sistema Urinário/metabolismoRESUMO
In vitro tachykinin-induced contractions of guinea pig ileum longitudinal smooth muscle were investigated under isometric conditions by using selective agonists ([Sar9,Met(O2)11]substance P, [Nle10]neurokinin A-(4-10), senktide) and antagonists (SR 140333, SR 48968, SR 142801), respectively, for the tachykinin NK1, NK2, and NK3 receptors. [Sar9,Met(O2)11]Substance P (10 nM) induced a tonic contraction with superimposed phasic contractions. Both tonic and phasic muscular activities were completely abolished by SR 140333 (10 nM) and were not modified by SR 142801 (10 nM). SR 48968 (10 nM) and atropine (0.001 mM) did not modify the tonic muscular activity but inhibited the phasic muscular activity. [Nle10]Neurokinin A-(4-10) (10 nM) only caused a phasic contractile response that was inhibited by SR 48968. Atropine, SR 140333, and SR 142801 were without effect. Senktide (1 nM) induced combined tonic and phasic contractile responses. SR 142801 blocked the phasic and tonic muscular activities, whereas SR 48968 and SR 140333 were inactive. After addition of atropine, only tonic contractile response was abolished. These results showed fundamental differences in isometric tonic and phasic contractile responses of guinea pig ileum longitudinal smooth muscle to tachykinins.
Assuntos
Contração Muscular/efeitos dos fármacos , Contração Muscular/fisiologia , Músculo Liso/efeitos dos fármacos , Músculo Liso/fisiologia , Taquicininas/farmacologia , Animais , Cobaias , Íleo/efeitos dos fármacos , Íleo/fisiologia , Técnicas In Vitro , Masculino , Neurocinina A/análogos & derivados , Neurocinina A/farmacologia , Fragmentos de Peptídeos/farmacologia , Substância P/análogos & derivados , Substância P/farmacologiaRESUMO
SR 121463A, a potent and selective, orally active, nonpeptide vasopressin V2 receptor antagonist, has been characterized in several in vitro and in vivo models. This compound displayed highly competitive and selective affinity for V2 receptors in rat, bovine and human kidney (0.6 < or = Ki [nM] < or = 4.1). In this latter preparation, SR 121463A potently antagonized arginine vasopressin (AVP)-stimulated adenylyl cyclase activity (Ki = 0.26+/-0.04 nM) without any intrinsic agonistic effect. In autoradiographic experiments performed in rat kidney sections, SR 121463A displaced [3H]AVP labeling especially in the medullo-papillary region and confirmed that it is a suitable tool for mapping V2 receptors. In comparison, the nonpeptide V2 antagonist, OPC-31260, showed much lower affinity for animal and human renal V2 receptors and lower efficacy to inhibit vasopressin-stimulated adenylyl cyclase (Ki in the 10 nanomolar range). Moreover, OPC-31260 exhibited a poor V2 selectivity profile and can be considered as a V2/V1a ligand. In normally hydrated conscious rats, SR 121463A induced powerful aquaresis after intravenous (0.003-0.3 mg/kg) or oral (0.03-10 mg/kg) administration. The effect was dose-dependent and lasted about 6 hours at the dose of 3 mg/kg p.o. OPC-31260 had a similar aquaretic profile but with markedly lower oral efficacy. The action of SR 121463A was purely aquaretic with no changes in urine Na+ and K+ excretions unlike that of known diuretic agents such as furosemide or hydrochlorothiazide. In addition, no antidiuretic properties have been detected with SR 121463A in vasopressin-deficient Brattleboro rats. Thus, SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.
Assuntos
Antagonistas dos Receptores de Hormônios Antidiuréticos , Morfolinas/farmacologia , Compostos de Espiro/farmacologia , Adenilil Ciclases/efeitos dos fármacos , Adenilil Ciclases/metabolismo , Administração Oral , Glândulas Suprarrenais/efeitos dos fármacos , Animais , Arginina Vasopressina/antagonistas & inibidores , Arginina Vasopressina/farmacologia , Autorradiografia , Benzazepinas/farmacologia , Ligação Competitiva , Furosemida/farmacologia , Hidroclorotiazida/farmacologia , Rim/efeitos dos fármacos , Estrutura Molecular , Potássio/urina , Ratos , Sódio/urina , UrinaRESUMO
It is now well-established that sensory nerves stimulation in the airway induces bronchoconstriction and inflammation, but also protective reflexes, such as coughing. These effects are mediated through the release of tachykinins (substance P and neurokinin A) and we have recently shown that SR 48968, a tachykinin NK2-receptor antagonist, inhibited cough induced by citric acid. In this paper, we have studied the effects of SR 48968 administered by aerosol. We have also investigated the effects of SR 140333, a tachykinin NK1-receptor antagonist, and the combination of both SR 48968 and SR140333 to determine whether tachykinin NK1 receptors are involved in cough. Finally, we have studied the combined effects of SR 48968 and salbutamol to find out whether the antitussive effect of SR 48968 is a consequence of the inhibition of bronchoconstriction. Unanaesthetized guinea-pigs were placed in a transparent chamber and exposed to an aerosol of citric acid (0.4 M). The number of coughs was counted by visual inspection and by determination of sounds and pressure variations in the chamber. By the aerosol route, SR 48968 was an efficient antitussive and 16 times more potent than codeine. SR 140333 (0.1-1 mg.kg-1 i.p.) did not exert any antitussive effect but it potentiated the maximal effect induced by SR 48968. Finally, salbutamol, in a dose (0.3 mg.kg-1) which inhibits bronchoconstriction, but not cough induced by citric acid, did not modify the antitussive effect of SR 48968.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Antitussígenos/farmacologia , Benzamidas/farmacologia , Tosse/tratamento farmacológico , Antagonistas dos Receptores de Neurocinina-1 , Piperidinas/farmacologia , Quinuclidinas/farmacologia , Receptores da Neurocinina-2/antagonistas & inibidores , Administração por Inalação , Aerossóis , Albuterol/farmacologia , Animais , Broncoconstrição/efeitos dos fármacos , Broncodilatadores/farmacologia , Codeína/farmacologia , Tosse/induzido quimicamente , Tosse/fisiopatologia , Sinergismo Farmacológico , Feminino , Cobaias , Masculino , Receptores da Neurocinina-1/fisiologia , Receptores da Neurocinina-2/fisiologia , EstereoisomerismoRESUMO
SR 142801 is the first potent and selective non-peptide antagonist of the tachykinin NK3 receptor. It inhibited [MePhe7]NKB binding to its receptor from various species, including humans. SR 142801 was a competitive antagonist of [MePhe7]NKB-mediated contractions of guinea-pig ileum and inhibited the acetylcholine release following the activation of the guinea-pig ileum tachykinin NK3 receptor. In vivo, SR 142801 potently inhibited the turning behaviour induced by intrastriatal injection of senktide in gerbils, and appears as a powerful tool for investigation of the physiological and pathological role of NKB and its NK3 receptor.
Assuntos
Piperidinas/farmacologia , Receptores da Neurocinina-3/antagonistas & inibidores , Animais , Comportamento Animal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Gerbillinae , Cobaias , Técnicas In Vitro , Neurocinina B/análogos & derivados , Neurocinina B/antagonistas & inibidores , Neurocinina B/metabolismo , Ratos , Vasoconstrição/efeitos dos fármacosRESUMO
(S)1-(2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)pip eridin-3- yl]ethyl)-4-phenyl-1-azoniabicyclo[2.2.2]octane chloride (SR140333) is a new non-peptide antagonist of tachykinin NK1 receptors. SR140333 potently, selectively and competitively inhibited substance P binding to NK1 receptors from various animal species, including humans. In vitro, it was a potent antagonist in functional assays for NK1 receptors such as [Sar9,Met(O2)11]substance P-induced endothelium-dependent relaxation of rabbit pulmonary artery and contraction of guinea-pig ileum. Up to 1 microM, it had no effect in bioassays for NK2 ([beta Ala8]neurokinin A-induced contraction of endothelium-deprived rabbit pulmonary artery) and NK3 ([MePhe7]neurokinin B-induced contraction of rat portal vein) receptors. The antagonism exerted by SR140333 toward NK1 receptors was apparently non-competitive, with pD2' values (antagonism potency evaluated by the negative logarithm of the molar concentration of antagonist that produces a 50% reduction of the maximal response to the agonist) between 9.65 and 10.16 in the different assays. SR140333 also blocked in vitro [Sar9,Met(O2)11]substance P-induced release of acetylcholine from rat striatum. In vivo, SR140333 exerted highly potent antagonism toward [Sar9,Met(O2)11]substance P-induced hypotension in dogs (ED50 = 3 micrograms/kg i.v.), bronchoconstriction in guinea-pig (ED50 = 42 micrograms/kg i.v.) and plasma extravasation in rats (ED50 = 7 micrograms/kg i.v.). Finally, it also blocked the activation of rat thalamic neurons after nociceptive stimulation (ED50 = 0.2 micrograms/kg i.v.).
Assuntos
Antagonistas dos Receptores de Neurocinina-1 , Piperidinas/farmacologia , Quinuclidinas/farmacologia , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Broncoconstrição/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Linhagem Celular , Cães , Endotélio Vascular/fisiologia , Cobaias , Humanos , Hipotensão/induzido quimicamente , Hipotensão/tratamento farmacológico , Masculino , Relaxamento Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Coelhos , Ratos , Ratos Sprague-Dawley , Receptores da Neurocinina-1/metabolismo , Substância P/análogos & derivados , Substância P/metabolismo , Substância P/farmacologia , Células Tumorais CultivadasRESUMO
The antitussive effects of SR 48968, a non-peptide tachykinin NK2 receptor antagonist, were investigated on citric acid-induced cough in the unanesthetized guinea-pig and compared with the effects of codeine. SR 48968 (0.01-0.3 mg/kg i.p.) inhibited in a dose-dependent manner the number of coughs induced by inhalation of an aqueous solution of citric acid with an ED50 of 0.1 mg/kg (0.17 mumol/kg). Under similar conditions, the codeine ED50 was 8 mg/kg (27 mumol/kg). Naloxone, an opioid receptor antagonist, abolished the effects of codeine but did not modify the effects of SR 48968. These data suggest that NK2 receptor stimulation might play an important role in the regulation of the cough reflex and that SR 48968 could be a potential antitussive agent.
Assuntos
Antitussígenos/farmacologia , Benzamidas/farmacologia , Tosse/tratamento farmacológico , Piperidinas/farmacologia , Receptores da Neurocinina-2/antagonistas & inibidores , Animais , Benzamidas/administração & dosagem , Citratos , Ácido Cítrico , Codeína/farmacologia , Tosse/induzido quimicamente , Relação Dose-Resposta a Droga , Feminino , Cobaias , Injeções Intraperitoneais , Masculino , Naloxona/farmacologia , Piperidinas/administração & dosagemRESUMO
Tachykinins produce concentration-dependent contraction of the human isolated bronchus by stimulation of receptors that belong to the NK2 type. The aim of this study was to investigate the inhibitory effects of a new, potent, and selective nonpeptide antagonist of the neurokinin A (NKA) (NK2) receptors, SR 48968 [(S)-N-methyl-N-[4-acetylamino-4-phenylpiperidino-2-(3,4-dichlorophenyl) butyl]benzamide] on human isolated airways. Our experiments were performed on human isolated bronchi obtained from patients with lung cancer. Phosphoramidon, 10(-5) M, was added to the bath to inhibit neurokinin metabolism. SR 48968 induced a parallel shift to the right of the concentration-response (C/R) curves to [Nle10]-NKA(4-10), a specific NK2 receptor agonist. The antagonism was of the competitive type, with a pA2 of 9.40 +/- 0.19 (slope = 0.95 +/- 0.08, n = 13). The (R)-enantiomer of SR 48968 was 100-fold less potent and a noncompetitive antagonist (slope = 0.56 +/- 0.11, n = 8); pA2 and slope of the racemate were 8.86 +/- 0.21 and 1.09 +/- 0.21 (n = 7), respectively. Under similar conditions, racemic CP-96,345, a nonpeptide NK1 antagonist, did not modify the C/R curves to [Nle10]-NKA(4-10) until 10(-7) M. SR 48968 did not modify C/R curves to acetylcholine, histamine, KCI, or PGF2 alpha on the human isolated bronchus. Finally, SR 48968 shifted to the right C/R curves to substance P on isolated human bronchi, whereas racemic CP-96,345 was without effect.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Benzamidas/farmacologia , Brônquios/efeitos dos fármacos , Neurocinina A/antagonistas & inibidores , Piperidinas/farmacologia , Receptores de Neurotransmissores/efeitos dos fármacos , Acetilcolina/administração & dosagem , Acetilcolina/farmacologia , Sequência de Aminoácidos , Animais , Benzamidas/administração & dosagem , Benzamidas/química , Compostos de Bifenilo/farmacologia , Broncoconstrição/efeitos dos fármacos , Cricetinae , Dinoprosta/administração & dosagem , Dinoprosta/farmacologia , Relação Dose-Resposta a Droga , Antagonismo de Drogas , Avaliação Pré-Clínica de Medicamentos , Feminino , Histamina/administração & dosagem , Histamina/farmacologia , Humanos , Técnicas In Vitro , Masculino , Pessoa de Meia-Idade , Dados de Sequência Molecular , Neurocinina A/efeitos dos fármacos , Fragmentos de Peptídeos/efeitos dos fármacos , Piperidinas/administração & dosagem , Piperidinas/química , Cloreto de Potássio/administração & dosagem , Cloreto de Potássio/farmacologia , Racemases e Epimerases , Receptores da Neurocinina-2 , Receptores de Neurotransmissores/classificaçãoRESUMO
The purpose of this study was to assess the effect of several drugs on the increase in cutaneous capillary permeability induced by intradermal injection of substance P (SP) and Sar9Met(O2)11-SP in guinea pig skin. On the one hand, the increase in cutaneous capillary permeability was partly reduced by spantide, promethazine, atropine or SR 40037, an inhibitor of the angiotensin-converting enzyme. On the other hand, norepinephrine and B3824, a B2-antagonist of bradykinin, showed an enhancing effect. Our results suggest that the effect of SP and Sar9Met(O2)11-SP in guinea pigs is partly mediated by histamine and acetylcholine, and that there is a relationship between tachykinins and bradykinin.
Assuntos
Permeabilidade Capilar/efeitos dos fármacos , Pele/irrigação sanguínea , Substância P/análogos & derivados , Substância P/farmacologia , Inibidores da Enzima Conversora de Angiotensina/farmacologia , Animais , Atropina/farmacologia , Corantes/farmacocinética , Fluoracetatos , Cobaias , Injeções Intradérmicas , Masculino , Norepinefrina/farmacologia , Oligopeptídeos/farmacologia , Compostos Orgânicos , Prometazina/farmacologiaRESUMO
SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. SR 48968 selectively inhibited neurokinin A binding to its receptor and was a competitive antagonist of neurokinin A-mediated contraction of different isolated smooth muscle preparations from various species including human. In vivo, the compound inhibited the bronchoconstriction induced by neurokinin A in guinea pigs. SR 48968 can be used to study the physiological or pathological role of neurokinin A and may be useful in the treatment of neurokinin A-dependent pathology.
Assuntos
Benzamidas/farmacologia , Neurocinina A/antagonistas & inibidores , Piperidinas , Receptores de Neurotransmissores/efeitos dos fármacos , Animais , Benzamidas/química , Ligação Competitiva , Broncoconstrição/efeitos dos fármacos , Cricetinae , Duodeno/metabolismo , Mucosa Intestinal/metabolismo , Coelhos , Ratos , Receptores da Neurocinina-2 , Vasoconstrição/efeitos dos fármacosRESUMO
Intragastric administration of the anti-arrhythmic drugs CM 7857 (Sanofi) or disopyramide, as expected, significantly reduced the heart rate in normal baboons at rest. At the same time, the variability in the heart rate increased. In vitro studies by Sanofi have previously shown the anti-arrhythmic effects of these drugs, i.e., a slowing of the transmembrane currents evidenced in several categories of heart cells especially when activated. Similar ion currents are known to be involved in extracardiac sensory-motor activities. However the H-reflex in soleus underwent no systematic changes in latency or amplitude with the drugs; the non-nociceptive early and nociceptive late polysynaptic responses elicited in the tibialis anterior muscle by sural nerve stimulation demonstrated a barely perceptible increase in integrated EMG value. No change could be seen in latency or amplitude of the cortical potentials evoked by sciatic or sural stimulation which was also used for reflex responses. Overall there was no definitive evidence of change in the extra-cardiac sensory-motor responses in the normal awake monkey, after administration of relatively high doses of the cardio-active compounds.
Assuntos
Antiarrítmicos/farmacologia , Disopiramida/farmacologia , Potenciais Somatossensoriais Evocados/efeitos dos fármacos , Propilaminas/farmacologia , Piridinas , Reflexo/efeitos dos fármacos , Medula Espinal/efeitos dos fármacos , Animais , Eletrocardiografia/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Papio , Respiração/efeitos dos fármacos , Medula Espinal/fisiologiaRESUMO
The antitussive and respiratory stimulant properties of N-(2'-ethylpyrrolidino)diphenylacetamide hydrochloride (F 1459) in animals are reported. In the mechanical stimulation of the trachea in guinea pigs and after intraperitoneal administration of the product, F 1459 showed a better antitussive action as compared to oxeladin, zipeprol, codeine and clobutinol. Low intraduodenal doses of F 1459 also reduced in cats the cough induced by the electrical stimulation of the superior laryngeal nerve. In anesthetized dogs whose respiratory functions had been depressed by morphine, F 1459 significantly increased the volume inspired per minute, an effect not due to any uncoupling effect on oxidative phosphorylation. F 1459 has local anesthetic and broncholytic properties that may play a role in the mechanism of its antitussive action. Contrarily to codeine, the test compound did not induce a decrease in the intestinal transit.
Assuntos
Antitussígenos , Pirrolidinas/farmacologia , Respiração/efeitos dos fármacos , Anestésicos Locais , Animais , Gasometria , Gatos , Cães , Interações Medicamentosas , Estimulação Elétrica , Feminino , Cobaias , Hemodinâmica/efeitos dos fármacos , Técnicas In Vitro , Lactatos/sangue , Ácido Láctico , Nervos Laríngeos/fisiologia , Masculino , Camundongos , Morfina/farmacologia , Estimulação Química , Traqueia/efeitos dos fármacosRESUMO
The authors describe the inhibiting action of mannitol after repeated administration of low subcutaneous doses in a number of experimental immunological models. For example, in the rat it produces a reduction of the secondary arthritis of Freund's adjuvant polyarthritis and also of the pleurisy due to Bordetella pertussis hypersensitivity. In the mouse it reduces the reaction of delayed hypersensitivity to sheep red cells. Its action is also marked against ovalbumin-induced active skin anaphylaxis in the albino guinea-pig and on IgE synthesis in the rat. Moreover, after several injections it produces a reduction of carbon phagocytosis in the mouse. At the doses at which the effect appeared, no action could be found on various models of acute non-immune inflammation, diuresis, blood pressure, hematocrit and protein and plasma sodium levels.